Prognostic value of the controlling nutritional status (CONUT) score in patients with diffuse large B-cell lymphoma: a meta-analysis

Table 4 Subgroup analysis of prognostic value of CONUT score for PFS in patients with DLBCL

Subgroups	No. of studies	No. of patients	Effects model	HR (95%CI)	p	Heterogeneity I²(%) Ph
Total	4	1134	Fixed	1.22(1.12–1.33)	< 0.001	0	0.548
Country
China	1	87	-	1.20(0.74–1.95)	0.453	-	-
Japan	1	476	-	1.42(0.98–2.06)	0.064	-	-
Turkey	1	266	-	1.19(1.08–1.31)	< 0.001	-	-
Korea	1	305		1.50(1.04–2.16)	0.030	-	-
Sample size
< 300	2	353	Fixed	1.19(1.08–1.31)	< 0.001	0	0.965
≥ 300	2	781	Fixed	1.46(1.12–1.89)	0.004	0	0.839
Treatment
R-CHOP	3	658	Fixed	1.21(1.10–1.32)	< 0.001	0	0.488
R-CHOP/R-THP-COP	1	476	-	1.42(0.98–2.06)	0.064	-	-
Cut-off value
< 5	2	742	Fixed	1.20(1.10–1.32)	< 0.001	0	0.367
≥ 5	2	392	Fixed	1.38(1.03–1.85)	0.029	0	0.476
Cut-off determination
ROC curve	2	742	Fixed	1.20(1.10–1.32)	< 0.001	0	0.367
Literature	2	392	Fixed	1.38(1.03–1.85)	0.029	0	0.476

R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-THP-COP, rituximab, cyclophosphamide, tetrahydropyranyl-adriamycin, vincristine, and prednisone; ROC, receiver operating characteristic; PFS, progression-free survival; CONUT, controlling nutritional status; DLBCL, diffuse large B-cell lymphoma

ISSN: 1477-7819